Key result
Among patients initially diagnosed with pure autonomic failure, 12% progressed to develop central nervous system involvement, most commonly multiple system atrophy.
Why the study?
What are the predictors of progression from pure autonomic failure to other synucleinopathies?
Population
318 patients seen at Mayo Clinic Rochester between 2001 and 2011 diagnosed with orthostatic hypotension…
Design
Cohort
Follow-up
≥3 years for stable PAF
Authors
Loading...
Patients with pure autonomic failure warrant surveillance for progression; observational data leave open validation of clinical predictors.
Cohort (n=318)
No
What are the predictors of progression from pure autonomic failure to other synucleinopathies?
Over 10% of patients initially diagnosed with pure autonomic failure eventually progress to central nervous system synucleinopathies, which can be predicted by specific clinical and autonomic variables.
Singer et al. (2017) conducted a cohort in Pure autonomic failure (n=318). Clinical, autonomic, and laboratory variables (e.g., supine norepinephrine >100 pg/mL) vs. Absence of predictor variables was evaluated on Progression to another synucleinopathy (MSA, PD, or DLB). Among patients initially diagnosed with pure autonomic failure, 12% progressed to develop central nervous system involvement, most commonly multiple system atrophy.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: